However, the resistance to such treatments often occurs and cancer cells that are resistant to tamoxifen15 or CDK4/6 inhibitor35 are still dependent on Cyclin D1 for proliferation, suggesting that alternative strategy is needed to block Cyclin D1 activity. This evidence concerns the gene CDK4 and cancer.